Cargando...
Erythropoietin as candidate for supportive treatment of severe COVID-19
In light of the present therapeutic situation in COVID-19, any measure to improve course and outcome of seriously affected individuals is of utmost importance. We recap here evidence that supports the use of human recombinant erythropoietin (EPO) for ameliorating course and outcome of seriously ill...
Guardado en:
| Publicado en: | Mol Med |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7297268/ https://ncbi.nlm.nih.gov/pubmed/32546125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10020-020-00186-y |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|